Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma | Zendy

Hervé Tilly | Zendy; Franck Morschhauser | Zendy; Laurie H. Sehn | Zendy; Jonathan W. Friedberg | Zendy; Marek Trněný | Zendy; Jeff P. Sharman | Zendy; Charles Herbaux | Zendy; John M. Burke | Zendy; Matthew J. Matasar | Zendy; Shinya Rai | Zendy; Koji Izutsu | Zendy; Neha MehtaShah | Zendy; Lucie Obéric | Zendy; Adrien Chauchet | Zendy; Wojciech Jurczak | Zendy; Yuqin Song | Zendy; Richard Greil | Zendy; Larysa Mykhalska | Zendy; Juan Bergua | Zendy; Matthew C. Cheung | Zendy; Antonio Pinto | Zendy; HoJin Shin | Zendy; Greg Hapgood | Zendy; Eduardo Munhoz | Zendy; Pau Abrisqueta | Zendy; JyhPyng Gau | Zendy; Jamie Hirata | Zendy; Yanwen Jiang | Zendy; Mark Yan | Zendy; Calvin Lee | Zendy; Christopher R. Flowers | Zendy; Gilles Salles | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Author(s) -

Hervé Tilly,

Franck Morschhauser,

Laurie H. Sehn,

Jonathan W. Friedberg,

Marek Trněný,

Jeff P. Sharman,

Charles Herbaux,

John M. Burke,

Matthew J. Matasar,

Shinya Rai,

Koji Izutsu,

Neha MehtaShah,

Lucie Obéric,

Adrien Chauchet,

Wojciech Jurczak,

Yuqin Song,

Richard Greil,

Larysa Mykhalska,

Juan Bergua,

Matthew C. Cheung,

Antonio Pinto,

HoJin Shin,

Greg Hapgood,

Eduardo Munhoz,

Pau Abrisqueta,

JyhPyng Gau,

Jamie Hirata,

Yanwen Jiang,

Mark Yan,

Calvin Lee,

Christopher R. Flowers,

Gilles Salles

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2115304

Subject(s) - medicine , rituximab , vincristine , hazard ratio , chop , diffuse large b cell lymphoma , gastroenterology , confidence interval , clinical endpoint , placebo , cyclophosphamide , prednisone , lymphoma , surgery , oncology , chemotherapy , randomized controlled trial , pathology , alternative medicine

Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured with R-CHOP. Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, which is ubiquitously expressed on the surface of malignant B cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research